Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Immunotherapy Logo (drop shadow)

PART OF NEXTGEN BIOMED 2026

24 - 25 March 2026 | QEII Centre, London, UK

+ WORKSHOP DAY ON 23 MARCH 2026

Programme Summary

A carefully curated event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of novel immunotherapies; advances in cellular, antibody and combination therapy development as well as personalised cancer therapy treatments.

Hear from past attendees of the NextGen Biomed 2025 conference

Build Your Personalised Agenda

See what you can't miss.

A personalised event programme built around your company, goals and interests — in seconds. No login required.

Untitled-3
Exhibitly AI Report Previews

DAY TWO

Immunotherapy & Immuno-oncology Keynote Address

ALEXANDER EGGERMONT, Professor, UMC Utrecht

Professor Eggermont is a melanoma specialist and immunotherapy development specialist. He trained at the Surgery Branch of the NCI (Steve Rosenberg) with a PhD in Tumor Immunology. He was the PI on multiple adjuvant immunotherapy trials in melanoma: FDA approvals in 2009 (Peg-IFN), 2015 (ipilimumab) and pembrolizumab (2019). Also TNF-isolated limb perfusion EMA approval in 1998 for advanced sarcomas of the extremities. Amongst his many honours includes the German Cancer Aid Award (2019) & the John Wayne Award of Clinical Research (2018).

2026 Highlights

Unlock the future of immunotherapy - from early discovery of novel cancer and
autoimmune targets to next-generation cancer vaccines. Explore how cutting-edge
biomarker and omics technologies are transforming translational insights into advanced
cell & gene therapies, predictive models, and precision medicine breakthroughs.

Unlock the future of precision immuno-oncology with cutting-edge biomarker
strategies—driving smarter combinations, sharper patient selection, and breakthrough
technologies that predict response and power truly personalised immunotherapy.

Explore the next wave of autoimmune disease therapies, from tolerisation
strategies to TCR and T cell–based approaches. Discover how advances in mRNA,
dendritic cell immunotherapy, and targeted antibody therapies are reprogramming the
immune system to deliver precise, lasting treatments for patients

NextGen Biomed - What to Expect Poster 2
NextGen Biomed - What to Expect Exhibiting 2
NextGen Biomed - What to Expect Networking 5
1000

leading pharma, biotech, regulatory & academic delegates

700
pre-arranged 1-2-1 meetings, facilitating business growth
50
hours of presentations, discussions & interactive content
12
hours of networking breaks, including fireside chats & refreshments
NGB + LSX Combined Logo-1

Unlock the Latest News and Insights

Sign-up for our regular LifeScienceXchange newsletter to keep up to date with all things NextGen Biomed, direct to your inbox.

NGB Newsletter Icon-1

Immunotherapy & Immuno-oncology Agenda at a Glance

DAY ONE - 24 MARCH

Track 8: Discovery & Development Of Therapies For Cancer & Autoimmune Diseases 
Track 9: Biomarker-Driven Personalised Immunotherapy 
Track 10: Next-Generation Targets & Emerging Therapeutic Platforms 

DAY TWO - 25 MARCH

Track 8: Enhancing Clinical Outcomes: Imaging, Modelling, Liquid Biopsy & Combination Strategies  
Track 9: Multi-Omics & Spatial Technologies in Immuno-Oncology
Track 10: Translational Models in Immuno-Oncology: In Vitro & In Vivo Approaches

NextGen Biomed Conference Brochure

Meet Our Expert Speakers

Immunotherapy & Immuno-oncology again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Alexander Eggermont
Professor, Clinical & Translational Immunotherapy,
UMC Utrecht
Annelise Vuidepot, PhD
Senior Vice President & Chief Technical Officer - Head of Pipeline & Platform Research and UK site Head,
Immunocore
Lilly Wollman
Chief Executive Officer,
Synteny
Livija Deban
Chief Scientific Officer,
Prokarium
May Sabry
Senior Director, Precision Medicine,
AstraZeneca
Simon Plyte
CSO,
Biomunex Pharmaceuticals
Show More Speakers
Hide Speakers
Ali Roghanian
Associate Professor in Cancer Immunotherapy,
University of Southampton
Allan Bradley
Founder, Director and Chief Scientific Officer,
T-Therapeutics
Apolline Lefevre
Clinical Pharmacology Sciences & Analytics,
Roche
Ayako Pedersen
Vice President Translational Research,
IO Biotech ApS
Brenda Iglesias
Associate Director, Strategic Partnerships,
GSK
Callum Scott
Head of Development,
Scancell Ltd
Christian Mueller
Chief Development Officer,
Immutep
Christian Garde
Director, Bioinformatics,
Evaxion AI
Colette Johnston
VP - Head of Product Platform Research,
Enara Bio
Darren Hodgson
Executive Director Cancer Biomarker Development,
AstraZeneca
Gabriel Wong
Senior Medical Director,
AstraZeneca
Hans Van Der Vliet
Chief Scientific Officer,
LAVA Therapeutics
Henoch Hong
Associate Director,
Merck Healthcare KGaA
James Legg
Chief Scientific Officer,
Cytospire Therapeutics
Jennifer Mataraza
Executive Director and Head, Translational Immuno-Oncology,
Novartis Institutes For Biomedical Research
Jerome Mastio
Associate principal scientist,
AstraZeneca
John Bridgeman
Chief Scientific Officer,
Immunokey
Kamaraj Karunanithi
Director of Research and Innovation,
University Hospitals of North Midlands NHS Trust
Larisa Soldatova
Professor & Reader in Data Science,
University of London
Maria Ascierto
Professor Translational Cancer Immunology; Head Scotland CRUK Clinical Biomarkers Hub,
University of Glasgow
Mariolina Salio
Director Experimental Immunology,
Immunocore
Markus Templin
Head - Cellular & Molecular Biology,
NMI
Miguel Gaspar
Senior Director, Oncology R&D,
Astrazeneca
Mihaela Bozic
Scientist,
T-Therapeutics Ltd
Ni Huang
Associate Director,
T-Therapeutics Ltd
Ricardo Carreira
Associate Director - Proteomics,
Immunocore
Sonia Macia
Chief Medical Officer,
OneChain Therapeutics
Sophia Karagiannis
Professor of Translational Cancer Immunology and Immunotherapy,
King's College London
Thakshila Liyanage
Founder/CEO,
Early is Good
Vaios Karanikas
Biomarker Portfolio Leader,
Roche
Vicky Brentville
Principle Scientist,
Scancell
Xi Zhao
Head, Oncology Bioinformatics, Research & Development,
AbbVie
Yi-Ru Yu
Lead Scientist,
Pilatus Biosciences SA

Interested in Sponsoring NextGen Biomed?

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients. NextGen Biomed offers a unique platform to enhance your brand visibility and connect with thousands of pharma, biotech, and R&D experts. Our branded event opportunities, immersive experiences, and content services enable you to engage, educate, and collaborate with the community shaping the future of biomedicine today.

Register Now

Be part of the new wave of Biomed R&D innovation

Partner with us

Become a driving force in accelerating the next generation of biologics and immunotherapy medicines to patients